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Introduction 
Carrier screening (CS) is a mechanism by which women and their 
partners can learn about their risks of having a child affected by a  
recessive genetic disorder.1 A carrier is a healthy individual who is not 
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or National Institutes of Health. The authors do not have any conflicts of 
interest to report. 
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Cleveland Clinic. 
1. Pascal Borry et al., Preconceptional Genetic Carrier Testing and the 
Commercial Offer Directly-to-Consumers, 26 Hum. Reprod. 972, 972-77 
(2011). 
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affected by genetic disease but nevertheless has one copy of a genetic  
mutation.2 Couples in which both individuals have a copy of the same 
genetic mutation are at increased risk of having a child who inherits the 
recessive genetic disorder.3 Theoretically, carrier identification and  
education regarding the inheritance of genetic mutations can serve as a 
form of “genotypic prevention” by enabling couples to prevent the genera-
tional transmission of specific genetic disorders.4 
CS typically takes place in the context of reproductive healthcare,5 
where results may be used to inform prospective parents of their options 
regarding family planning and prenatal diagnosis.6 CS is typically  
recommended on the basis of a family history of a genetic condition and 
for populations that have higher incidences of recessive conditions such 
as the Ashkenazi Jewish population.7 Some medical professional societies 
have recommended shifting away from targeting CS based on family 
history and ethnicity toward population-based CS for all women who are 
considering pregnancy or are already pregnant,8 specifically to screen for 
 
2. Thomas W. Prior, Carrier Screening for Spinal Muscular Atrophy, 10 
Genetics Medicine 840, 842 (2008). 
3. Jeffrey R. Botkin, Assessing the New Criteria for Newborn Screening, 19 
Health Matrix 163, 177 (2009). 
4. Eric T. Juengst, Population Genetic Research and Screening: Conceptual 
and Ethical Issues, in Oxford Handbook of Bioethics 471, 480-82, 484-
85 (Bonnie Steinbock ed., 2006). 
5. See Teresa Doksum et al., Carrier Screening for Cystic Fibrosis Among 
Maryland Obstetricians Before and After the 1997 NIH Consensus 
Conference, 5 Genetic Testing 111, 111 (2001). 
6. Kathleen J.H. Sparbel & Janet K. Williams, Pregnancy as Foreground in 
Cystic Fibrosis Carrier Testing Decisions in Primary Care, 13 Genetic 
Testing & Molecular Biomarkers 133, 140 (2009). 
7. Susan J. Gross et al., Carrier Screening in Individuals of Ashkenazi Jewish 
Descent, 10 Genetics Medicine 54, 54-56 (2008); Siobhan M. Dolan & 
Cynthia Moore, Linking Family History in Obstetric and Pediatric Care: 
Assessing Risk for Genetic Disease and Birth Defects, 120 Pediatrics 
S66, S68 (Supp. II 2007); David Kronn et al., Carrier Screening for Cystic 
Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish 
Population, 158 Archives Internal Med. 777, 777 (1998). 
8. See Wayne W. Grody et al., Laboratory Standards and Guidelines for 
Population-Based Cystic Fibrosis Carrier Screening, 3 Genetics Med. 
149, 150 (2001); Beth A. Pletcher et al., The Future is Now: Carrier 
Screening for All Populations, 10 Genetics Medicine 33, 33, 35 (2008); 
Michael S. Watson et al., Cystic Fibrosis Population Carrier Screening: 
2004 Revision of American College of Medical Genetics Mutation Panel, 6 
Genetics Medicine 387, 387 (2004); Prior, supra note 2, at 842;  
Am. Coll. of Obstetricians & Gynecologists Comm. on Genetics, Committee 
Opinion No. 486: Update on Carrier Screening for Cystic Fibrosis, 117 
Obstetrics & Gynecology 1028, 1030 (2011). 
Health Matrix·Volume 23·Issue 1·2013 
The Changing Landscape of Carrier Screening 
17 
carrier status for cystic fibrosis (CF)9 and spinal muscular atrophy 
(SMA).10 
In the last few years, CS panels11 have expanded to evaluate large 
numbers of mutations associated with a range of autosomal recessive and 
X-chromosome-linked inherited conditions including CF, SMA, Tay-Sachs 
Disease, sickle cell anemia, and Fragile X syndrome.12 Several commercial 
laboratories have developed these expanded CS panels and market them 
to reproductive healthcare providers.13 Despite the changing technological 
and commercial landscape of CS in the United States, little is known 
about the clinical and societal implications of expanding CS efforts to  
include and detect much larger numbers of genetic disorders. To this end, 
we report results of a study of professionals with expertise in genetics  
regarding their attitudes toward prenatal applications of expanded carrier 
screening (ECS). A primary aim of this paper is to describe genetics  
professionals’ perceptions of the benefits and challenges of expanding pre-
 
9. Cystic fibrosis is a childhood onset genetic disorder inherited in an 
autosomal recessive manner that affects the lungs and digestive system. It 
is the most common life-limiting inherited disorder in the Caucasian 
population.  See Sparbel & Williams, supra note 6, at 133-34.  
10. Spinal muscular atrophy is a childhood- or adult-onset life-limiting 
neuromuscular disorder that is inherited in an autosomal recessive manner.  
Prior, supra note 2, at 840.  
11. A panel is a carrier screening platform that “test[s] for several disorders as 
a group, in a single multiplex assay.”  See Gross et al., supra note 7, at 56.  
12. Balaji S. Srinivasan et al., A Universal Carrier Test for the Long Tail of 
Mendelian Disease, 21 Reprod. BioMedicine Online 537, 538-39 (2010); 
see Women’s Health – For Physicians, GenPath, 
http://www.genpathdiagnostics.com/womens-health/inherigen/ (last visited 
Jan. 3, 2013); Explanation of Carrier Status and Disease Risk, 23andMe, 
Inc., http://www.23andme.com/health/carrier/ (last visited Jan. 3, 2013).  
Tay-Sachs disease is fatal childhood onset condition that is inherited in an 
autosomal recessive manner.  Carrier screening for Tay-Sachs is targeted 
toward the Ashkenazi Jewish ethnic population due to carrier prevalence.  
Kronn et al., supra note 7, at 777.  Sickle cell anemia is a hemoglobinopathy 
that primarily affects populations with African, Mediterranean and Middle 
Eastern ancestry.  See Sickle Cell Anemia & Malaria Resistance, 23andMe, 
Inc., https://www.23andme.com/health/Sickle-Cell-Anemia-Malaria-
Resistance/ (last visited Jan. 3, 2013) (explaining that sickle cell anemia 
distorts the shape of red blood cells and primarily affects those with 
“ancestors who lived in Africa, the Mediterranean, India, or the Middle East 
within the last thousand years”).  Fragile X syndrome is the most common 
form of inherited intellectual disability.  Fragile X Syndrome, Counsyl, 
https://www.counsyl.com/diseases/fragile-x-syndrome (last visited Jan. 3, 
2013).   
13. See Counsyl, https://www.counsyl.com (last visited Jan. 3, 2013); Ambry 
Genetics, http://www.ambrygen.com (last visited Jan. 3, 2013); GenPath, 
http://www.genpathdiagnostics.com (last visited Jan. 3, 2013); Pathway 
Genomics, https://www.pathway.com (last visited Jan. 3, 2013); see 23andMe, 
Inc., http://www.23andme.com (last visited Jan. 3, 2013). 
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natal CS. A secondary aim is to situate these genetics professionals’ per-
spectives within the broader landscape of societal debates about  
appropriate integration of new risk assessment technologies into prenatal 
care. The results and following discussion demonstrate how new approaches 
to CS both resemble and diverge from previous prenatal surveillance tech-
nologies in ways that are likely to impact clinical practice and pregnant 
women’s reproductive choices and perceived responsibilities. 
I. Current Approaches to Carrier Screening 
Medical professionals advocate CS prior to pregnancy because a  
wider array of reproductive options is available to prospective parents 
before pregnancy than during it, including deciding whether and how to 
conceive and considering assisted reproductive technologies such as  
embryonic genetic testing or donor gametes.14 Pregnant women and their 
partners who receive positive CS results are limited to either  
(1) accepting the possible risk and continuing the pregnancy or  
(2) undergoing prenatal diagnosis and potentially deciding whether to 
terminate or continue an affected pregnancy.15 However, preconception 
applications of CS are logistically challenging: nearly half of all pregnan-
cies in the United States are unplanned, and non-pregnant patients are 
typically not interested in seeking population-based preconception carrier 
testing.16 As a result, CS is typically offered during pregnancy by prena-
tal care providers, including obstetricians, nurse midwives, and family 
practitioners who deliver babies.17 However, there is evidence that not all 
obstetricians and gynecologists adhere to professional guidelines for pop-
ulation-based CS.18 To the extent that genetic counselors are involved in 
 
14. See Sparbel, supra note 6, at 140; Sylvia A. Metcalfe, Carrier Screening in 
Preconception Consultation in Primary Care, 3 J. Community 
Genetics 193, 193-94 (2012); see Guido M. W. R. De Wert et al., 
Preconception Care and Genetic Risk: Ethical Issues, 3 J. Community 
Genetics 221, 221 (2012).  
15. De Wert et al., supra note 14, at 225-26. 
16. See Ellen Wright Clayton et al., Lack of Interest by Nonpregnant Couples 
in Population-Based Cystic Fibrosis Carrier Screening,  
58 Am. J. Hum. Genetics 617, 626 (1996); Lawrence B. Finer & Stanley 
K. Henshaw, Disparities in Rates of Unintended Pregnancy in the United 
States, 1994 and 2001, 38 Persp. on Sexual Reprod. Health 90, 90 
(2006). 
17. S. Loader et al., Cystic Fibrosis Carrier Population Screening in the 
Primary Care Setting, 59 Am. J. Hum. Genetics 234, 235 (1996); see 
Jeffrey C. Levenkron et al., Carrier Screening for Cystic Fibrosis: Test 
Acceptance and One Year Follow-Up, 73 Am. J. Med. Genetics 378, 379 
(1997); David R. Witt et al., Cystic Fibrosis Heterozygote Screening in 
5,161 Pregnant Women, 58 Am. J. Hum. Genetics 823, 824 (1996). 
18. Maria A. Morgan et al., Practice Patterns of Obstetrician-Gynecologists 
Regarding Preconception and Prenatal Screening for Cystic Fibrosis,  
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counseling regarding CS, their involvement tends to occur after a woman 
and her partner receive a positive result.19  
In addition to variability of CS practices across health care providers 
and patient populations, research has also shown that education and 
values impact patient willingness to consider CS in the reproductive 
context. Empirical research suggests that pregnancy itself is a lens 
through which women make decisions about whether to accept carrier 
testing, whereby “underlying belief systems, heightened vulnerability and 
personal stress management strategies” influence decision-making during 
pregnancy.20 For instance, Sparbel and Williams found that pregnant 
women who were committed and attached to their pregnancies were less 
likely to accept carrier testing to avoid heightening their anxiety and 
stress.21 Hence, some have argued that education and informed consent 
for CS should be tailored to patient values and expectations, as educa-
tional needs for making an informed decision about whether to undergo 
screening differ depending on patient values.22 However, existing research 
assessing educational needs and values has been limited to assessing CS 
for single gene disorders, and little is known about how the expansion of 
CS panels might impact clinical practice and patient uptake. 
II. The Emergence of Expanded Carrier Screening 
Despite evidence that there are multiple challenges associated with 
the integration of population-based approaches to CS into reproductive 
healthcare, several commercial laboratories are beginning to advocate 
ECS. The Universal Genetic Test marketed by Counsyl was the first of 
these products to become available through select clinics across the 
 
6 Genetics Medicine 450, 450 (2004); Diana Darcy et al., Cystic Fibrosis 
Carrier Screening in Obstetric Clinical Practice: Knowledge, Practices, 
and Barriers, a Decade After Publication of Screening Guidelines, 15 
Genetic Testing & Molecular Biomarkers 517, 517 (2011). 
19. Genetic counselors are health care providers who serve as genetics 
educators for patients and other clinicians. They provide information and 
support to patients about what it means to be a carrier of a genetic 
mutation and how positive test results can impact decisions regarding 
prenatal diagnosis and managing the pregnancy, including the possibility of 
pregnancy termination.  A Guide to Genetic Counseling 4-5 (Wendy 
R. Uhlmann et al. eds., 2d ed. 2009); Elinor Langfelder-Schwind et al., 
Cystic Fibrosis Prenatal Screening in Genetic Counseling Practice: 
Recommendations of the National Society of Genetic Counselors, J. 
Genetic Counseling, Feb. 2005, at 1, 3. 
20. Sparbel, supra note 6, at 139. 
21. Id. at 138-39. 
22. K.E. Ormond et al., What Do Patients Prefer: Informed Consent Models 
for Genetic Carrier Testing, 16 J. Genetic Counseling 539, 547 (2007).   
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United States.23 Unlike population-based CS for individual genetic disor-
ders (e.g., CF and SMA) which is largely administered during pregnancy 
and CS panels targeted towards specific ethnic populations (e.g., the 
Ashkenazi Jewish Genetic Panel), the Universal Genetic Test was mar-
keted as a preconception CS panel that would be universally-applicable 
to all ethnic populations due to the inclusion of genetic mutations that 
are common across ethnic groups.24 
Since 2009, four additional products have become available: Ambry 
Genetics’ AmbrySCREEN,25 GenPath’s InheriGen,26 Pathway Genomics’ 
Pre-Pregnancy Planning Insight,27 and 23andMe’s Personal Genome  
Service.28 The five currently available products screen for 47 to 164 auto-
somal recessive and X-chromosome-linked conditions that range in 
severity and age of onset from fatal, childhood-onset conditions to adult-
onset conditions.29 With declining genotyping costs and a thriving  
commercial market for genetic testing products, it is reasonable to ex-
pect that the number of genetic conditions and mutations evaluated by  
carrier testing products will continue to increase.30  
23. The Need for a Universal Test, Counsyl, https://www.counsyl.com/ 
learn/minority/ (last visited Jan. 3, 2013). 
24. Srinivasan, supra note 12, at 538-39. 
25. See Carrier Screening and Prenatal, Ambry Genetics, 
http://www.ambrygen.com/carrier-screening-and-prenatal (last visited Jan. 
3, 2013). 
26. See Women’s Health – For Physicians, GenPath,
 http://www.genpathdiagnostics.com/womens-health/inherigen/ (last 
visited Jan. 3, 2013). 
27. Pre-Pregnancy Planning Insight, Pathway Genomics, https:// 
www.pathway.com/dna-reports/carrier-status (last visited Jan. 3, 2013). 
28. Explanation of Carrier Status and Disease Risk, 23andMe, Inc.,
http://www.23andme.com/health/carrier/ (last visited Jan. 3, 2013). 
29. See One Test for 100+ Genetic Diseases, Counsyl,
https://www.counsyl.com/diseases/ (last visited Jan. 3, 2013); Tests by 
Disease, AMBRY GENETICS, http://www.ambrygen.com/tests-by-disease (last 
visited Jan. 3, 2013); Women’s Health –  For Physicians, GenPath,
http://www.genpathdiagnostics.com/womens-health/inherigen/ (last visited 
Jan. 3, 2013); Pre-Pregnancy Planning Insight, Pathway Genomics, 
https://www.pathway.com/dna-reports/carrier-status (last visited Jan. 3, 
2013); Explanation of Carrier Status and Disease Risk, 23andMe, Inc., 
http://www.23andme.com/health/carrier (last visited Jan. 3, 2013). 
30. See Callum J. Bell et al., Carrier Testing for Severe Childhood Recessive 
Diseases by Next-Generation Sequencing, 3 Sci. Translational Med., 
Jan. 12, 2011, 65ra4, 3 (indicating that over 102,000 disease mutations 
have been identified to date).  Geneticists argue that next-generation 
sequencing technologies are likely capable of evaluating more recessive 
carrier traits without significantly increasing the cost of CS. See Laird 
Jackson & Reed E. Pyeritz, Molecular Technologies Open New Clinical 
Genetic Vistas, Sci. Translational Med., Jan. 12, 2011, 65ps2, 3; De 
Wert et al., supra note 14, at 227. 
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These products are marketed primarily as preconception CS tools to 
be used by prospective mothers and fathers,31 though there is some  
evidence that ECS is available to prenatal patients as well.32 If used in 
the prenatal context, ECS of the mother may be followed by diagnostic 
testing of the fetus.33 
Current ECS products screen a patient-provided saliva or blood 
sample for known mutations at loci associated with recessive diseases.34 
The patient or physician can expect results in approximately two to 
three weeks.35 Prices range from $99 to $450, which is within the range 
of the costs traditionally associated with evaluation of carrier status for 
single disorders such as CF or SMA.36 Most products are offered only 
through a physician,37 although one product is available for purchase 
direct-to-consumer via the Internet.38 While one product advertises its 
availability at “100s of clinics across the US,”39 information regarding 
 
31. MDs Recommend Offering Testing, Counsyl, https://www.counsyl.com 
/learn/lifesaving/ (last visited Jan. 3, 2013); see Pre-Pregnancy Planning 
Insight, Pathway Genomics, https://www.pathway.com/ 
dna-reports/carrier-status (last visited Jan. 3, 2013). 
32. See Women’s Health – For Physicians, GenPath,
http://www.genpathdiagnostics.com/womens-health/inherigen/ (last 
visited Jan. 3, 2013) (“InheriGen is intended for an individual at a 
reproductive age as a preconception or prenatal screen to determine if 
he/she carries one or more mutations for inherited diseases.”).  
33. See id. 
34. See, e.g., How To Use a Saliva or Blood Collection Kit, Counsyl, 
https://www.counsyl.com/howto/ (last visited Jan. 3, 2013). 
35. See, e.g., Before Pregnancy, One Simple Test, Counsyl,
 https://www.counsyl.com/ (last visited Jan. 3, 2013); Tests by Disease, 
AMBRY GENETICS, http://www.ambrygen.com/tests-by-disease (last visited 
Jan. 3, 2013); 23andMe Store, 23andMe, Inc., 
https://www.23andme.com/store/cart/ (last visited Jan. 3, 2013). 
36. Cystic Fibrosis Genetic Testing Basics, Aetna InteliHealth, 
http://www.intelihealth.com/IH/ihtIH/WSIHW000/32193/32202/361128.h
tml?d=dmtContent (last updated June 28, 2011); Sarah E. Little et al., 
The Cost-Effectiveness of Prenatal Screening for Spinal Muscular Atrophy, 
202 Am. J. Obstetrics & Gynecology 253.e1, 253.e3 (2010). 
37. See Easy to Use, Counsyl, https://www.counsyl.com/learn/easy/ (last 
visited Jan. 3, 2013); To Get Tested, Ambry Genetics, 
http://www.ambrygen.com/get-tested (last visited Jan. 3, 2013); Women’s 
Health – For Physicians, GenPath,
http://www.genpathdiagnostics.com/womens-health/inherigen/ (last 
visited Jan. 3, 2013); Pre-Pregnancy Planning Insight, Pathway 
Genomics, https://www.pathway.com/dna-reports/carrier-status (last 
visited Jan. 3, 2013). 
38. Explanation of Carrier Status and Disease Risk, 23andMe, Inc.,
http://www.23andme.com/health/carrier/ (last visited Jan. 3, 2013). 
39. Counsyl, https://www.counsyl.com (last visited Jan. 3, 2013). 
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uptake of these products is not available currently. In addition, there are 
no medical consensus statements or professional-society guidelines  
regarding the use of ECS products in preconception or prenatal care. 
III. Focus-Group Study 
Focus-group methodology was used to examine genetics 
professionals’ perspectives on the expansion of CS. This methodology is 
ideal for collecting in-depth qualitative data, as focus groups involve 
small gatherings of knowledgeable individuals who share a common set 
of interests for a moderated discussion of a chosen topic.40 Focus-group 
methodology is particularly useful for producing data through social  
interaction that allows participants to make comparisons between each 
others’ experiences and opinions.41 This approach enables participants to 
react to and build on responses from their colleagues, resulting in novel 
opportunities for the production of ideas and the identification of areas 
of disagreement and agreement.42 The focus-group sessions reported here 
comprise a component of a larger study to assess genetics professionals’ 
perspectives on the impact of genomic tests on clinical practice.43 
To promote professional and specialist diversity in each focus group, 
a purposive sampling strategy was used to identify experts in medical 
genetics and genetic counseling at academic medical centers with well-
established genetics programs. The research team organized focus groups 
in Ann Arbor, Michigan; Baltimore, Maryland; Cleveland, Ohio; Denver, 
Colorado; Philadelphia, Pennsylvania; and Seattle, Washington. Sites 
were selected based on their geographical location, training programs in 
medical genetics and genetic counseling, translational research programs, 
and clinical practice settings (e.g., pediatric vs. adult clinics, public vs. 
private institutions, etc.). With approval of the institutional review 
board at each study site, collaborators at the Cleveland Clinic, Johns 
Hopkins University, University of Colorado, University of Michigan, 
University of Pennsylvania, and University of Washington assisted in 
 
40. Sharan B. Merriam, Qualitative Research: A Guide to Design 
and Implementation 93-94 (3d ed. 2009); Phil Macnaghten & Greg 
Myers, Focus Groups, in Qualitative Research Practice 65, 65 
(Clive Seale et al. eds., 2004). 
41. Morgan et al., supra note 18, at 450.   
42. Jenny Kitzinger, The Methodology of Focus Groups: The Importance of 
Interaction between Research Participants, 16 Sociology of Health & 
Illness 103, 107 (1994); David W. Stewart et al., Focus Groups: 
Theory and Practice 43 (2d ed. 2007). 
43. See generally Wendy R. Uhlmann & Richard R. Sharp, Genetic Testing 
Integration Panels (GTIPs): A Novel Approach for Considering 
Integration of Direct-to-Consumer and Other Tests into Patient Care, 21 
J. Genetic Counseling 374 (2012). 
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identifying participants with appropriate expertise in genetics, including 
specialists in medical genetics, pediatric genetics, genetic counseling, 
public-health genetics, primary-care medicine, laboratory medicine, 
health communication, law, and bioethics. These individuals were  
approached by the Principal Investigator, R.S., and recruited to partici-
pate in focus-group sessions. Participants provided written consent to 
participate and received $100 for their participation.  
Six focus-group sessions exploring ECS were conducted in March 
2011. A clinical case report was presented to each focus group to  
examine participants’ opinions about the use of ECS in reproductive 
healthcare. This case report consisted of a hypothetical patient’s medical 
history, reasons for seeking reproductive counseling, and an anonymous 
laboratory report presenting ECS results from a commercial laboratory. 
This laboratory was not involved in any aspect of this study. The ECS 
product discussed at the focus group sessions must be ordered by a  
licensed physician and evaluates approximately 350 recessive mutations 
associated with 78 genetic diseases. R.S. served as a facilitator for the 
focus groups and used a moderator guide to promote consistency across 
sites. 
Discussions of ECS lasted approximately 30-60 minutes. Participants 
were asked to consider how they would prepare for a clinical appointment 
in which they reported test results to this hypothetical patient and coun-
seled her about reproductive implications. Additional questions examined 
participants’ attitudes about the clinical implementation of ECS, including 
participants’ opinions about whether ECS might be preferable to more 
targeted approaches to CS based on a patient’s family history or ethnicity. 
Participants were asked to identify potential challenges in the interpreta-
tion and communication of ECS results and to describe their overall levels 
of enthusiasm for ECS. 
Focus-group discussions were audio-taped and transcribed to enable 
thematic analysis by independent review and consensus-building confer-
ences.44 To promote and construct validity and reliability of conceptual 
domains identified through coding, M.M. and D.C. analyzed focus-group 
transcripts to capture themes and concepts related to applications of 
ECS using qualitative data analysis software (ATLAS.ti v5.8). Using 
methods prescribed by grounded theory,45 analysts developed their inter-
pretations of the themes though review of the coded transcripts. The 
hypothetical case study presented to focus group participants dealt with 
a preconception CS scenario, and findings related to preconception 
 
44. Nancy L. Kondracki et al., Content Analysis: Review of Methods and Their 
Applications in Nutrition Education, 34 J. Nutrition Educ. & Behav. 
224, 224-25 (2002). 
45. See generally Juliet Corbin & Anselm Straus, Grounded Theory Research: 
Procedures, Canons, and Evaluative Criteria, 13 Qualitative Sociology 
3, 5-6 (1990) (providing a brief overview of grounded theory). 
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applications of ECS will be presented elsewhere. Thematic analysis 
presented here is limited to examining participants’ opinions of prenatal 
applications of ECS. 
IV. Results 
Forty genetic professionals participated in six focus groups for this 
study. Four themes related to prenatal applications of ECS emerged from 
the focus-group discussion transcripts.46 First, participants suggested that 
the appeal of ECS in the prenatal context may be that it tests for more 
risk factors at a comparable or lower cost than standard CS. Second, par-
ticipants felt that the marketing of ECS as a preconception CS tool was 
not likely to have an impact on the timing in which CS tends to be  
introduced into patient care. Third, participants felt that uptake of ECS 
may foster a defensive approach to prenatal care for both clinicians and 
pregnant women. Fourth, participants stressed that informed-consent 
practices for prenatal screening tend to be inadequate and that the  
challenges associated with effective prenatal risk counseling may be  
exacerbated in the context of ECS. We present these major findings in 
greater detail below. 
Participants suggested that the appeal of ECS in the prenatal  
context may be that it assesses more risk factors at a comparable or 
lower cost than other targeted and population-based CS tools. As one 
participant explained:  
I’ve talked with some of the prenatal counselors about these tests and 
I think there is still a debate about exactly how to handle them  
because it is such large testing and for people who aren’t seeing these 
conditions all of the time it gets harder to counsel about it. But I 
think a lot of people are feeling more like if you’re going to offer CF 
screening, you might as well . . . just offer the whole thing.47 
Although ECS was attractive to some participants based on its cost and 
scope of coverage, others noted that even women who might want to 
avoid invasive prenatal diagnosis are still likely to be offered some forms 
of genetic screening during pregnancy, especially if preconception CS 
results or maternal age indicates increased risk for the child.48 
Notably, participants cited the commonality of prenatal (as opposed 
to preconception) screening for carrier status for CF and Tay-Sachs  
disease. Participants rejected the idea that the commercial availability of 
 
46. The institutional review board-approved research protocol requires that 
focus group transcripts remain confidential and on file with study 
personnel.  Please direct any queries about the focus group data to Dr. 
Richard Sharp (sharpr3@ccf.org).  
47. Focus Group 2. 
48. Focus Groups 2–6. 
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ECS panels would have an impact on when CS is introduced to patients.49 
Rather, participants remarked that preconception genetic counseling is 
atypical and that patients are much more likely to be introduced to CS for 
the first time when they are already pregnant.50 Although these products 
are primarily marketed as preconception risk assessment tools, one partic-
ipant explained, “[i]t is worth noting that these tests are used prenatally, 
they’re not used pre-conception . . . . The language is around  
preconception because that’s what . . . the companies want to sell, but the 
testing is actually done after a woman’s pregnant.”51 
In contrast to screening for aneuploidies52 and other prenatal risk  
factors that are not related to genetic contributions from the parents,  
participants characterized CS as “one of the areas where it is easier to 
walk parents through the choices that they have.”53 However, they 
acknowledged that these choices are constrained and potentially difficult 
for pregnant women and their partners because reproductive options that 
are available to those receiving positive CS results in the context of an 
ongoing pregnancy are all reactive as opposed to proactive.54 Participants 
explained that the pathways that were available to pregnant women and 
their partners include prenatal diagnosis followed by possible termination 
of the pregnancy if a fetus is affected by mutation in question or continua-
tion of the pregnancy without additional testing of the fetus and accepting 
the risk of having an affected child.55 
While these reproductive options may be confounding for prospective 
parents, participants noted that increasing use of ECS by clinicians and 
pregnant women may signal a more defensive approach to risk  
identification and management.56 As one participant elaborated:  
This is going to be really driven on the defensive medicine side, right? 
So we know for a fact that there are wrongful birth causes of action 
 
49. Focus Groups 2 & 6. 
50. Focus Groups 5 & 6. 
51. Focus Group 6. 
52. Aneuploidies involve a chromosomal imbalance in which the fetus has more 
or fewer chromosomes than is typical.  Trisomy 21 (Down syndrome) is an 
example in which the fetus has three copies of the twenty-first chromosome 
rather than the typical two.  Risk of aneuploid pregnancies is not related 
to the genetic contribution of carrier traits by the mother and father. 
However, risk of aneuploid pregnancies is heightened as maternal age 
increases. See Clare O’Connor, Chromosomal Abnormalities: Aneuploidies, 
1 Nature Educ. 1 (2008), available at http://www.nature.com/scitable/ 
topicpage/chromosomal-abnormalities-aneuploidies-290. 
53. Focus Group 3. 
54. Focus Groups 3 & 6. 
55. Focus Groups 5 & 6. 
56. Focus Groups 3 & 6. 
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that go through because you’ve failed to pick up something that you 
needed to pick up in a test. So this will drive both sides—certainly 
the medical side to use the most comprehensive test possible—but 
there’s also enormous pressure, I think, on women in particular to, 
you know, take whatever step you can take to have a healthy baby, 
as crazy as that stuff is going to be . . . . When you look at some of 
the psychological literature about why women agree to testing during 
pregnancy even some of whom will say, “But I would never, I would 
never abort the fetus,” but who will still agree to do the testing. It’s 
sort of an interesting—and they’re not saying it just because I want 
to know the information, they feel very pressured to do things.57 
This quote suggests that among future users of ECS products, many  
may be clinicians hoping to avoid wrongful birth lawsuits and pregnant 
patients who want to avoid having children with detectable genetic  
diseases. Participants noted that this defensive stance could be challenging  
in two ways: while ECS may assess risks that standard approaches to 
population-based CS would miss, it does not assess every possible repro-
ductive risk factor. Some participants cautioned, for instance, that ECS 
products do not evaluate a woman’s risk of having a child with chromo-
somal anomalies such as aneuploidies (which increases as a woman ages), 
so ECS should not be considered adequate for assessing all genetic and 
chromosomal risks.58 Participants cautioned that a defensive approach to 
CS could be confusing for both clinicians and patients given that ECS is 
more inclusive but not comprehensive in its assessment of genetic and 
chromosomal risks.59 
Illustrating the complexities of integrating new and more complex 
risk assessment tools into prenatal screening and testing, one participant 
drew parallels between ECS and cell-free fetal DNA testing,60 saying that 
both of these emerging tools are “not quite ready for prime time.”61  
Despite their professional assessments that new prenatal screening tools 
were outpacing clinicians’ capabilities to develop plans for responsive 
integration of these genetic technologies into healthcare, participants 
argued that reproductive specialists can impact the integration of ECS in 
important ways, such as by developing appropriate strategies for  
obtaining informed consent and providing effective pre-test counseling.62  
57. Focus Group 3. 
58. Focus Groups 1–3. 
59. Focus Groups 1, 3–4. 
60. Jaime S. King, And Genetic Testing for All . . . The Coming Revolution in 
Non-Invasive Prenatal Genetic Testing, 42 Rutgers L.J. 599, 600 (2011) 
(explaining that cell-free fetal DNA testing is a prenatal screening of 
maternal blood to evaluate fetal DNA fragments for risk of trisomies 13, 18 
and 21). 
61. Focus Group 6. 
62. Focus Groups 2, 4–6. 
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Participants agreed that uptake of ECS by pregnant women should 
be voluntary, but they acknowledged that prenatal testing is sometimes 
undertaken without adequate informed consent.63 Giving the example 
that many pregnant women do not know that they have undergone  
routine prenatal genetic screening if it only involves a blood draw,64 one 
participant noted: 
I think that these [ECS panels] are going to be marketed to OBs, 
and they’re just going to do them without a conversation. The 
same as they kind of do triple screens and quad screens without 
much of a conversation for pregnant women; and then we’re  
[genetic professionals are] going to be left hoping that we can help 
with the interpretation.65 
Participants in another focus group also stressed that obtaining informed 
consent would be especially challenging in the context of ECS because of 
the wider range of disease risks assessed.66 The previous quote also  
illustrates that specialists in genetics saw themselves as being put in the 
position to interpret ECS results that were ordered by other clinicians, 
perhaps with inadequate pre-test counseling. In this context, genetic 
professionals were especially concerned that pregnant women and couples 
may not appreciate that pursuing ECS may later require them to  
consider prenatal diagnosis and possibly pregnancy termination based on 
genetic findings.67 The general consensus among participants was that 
the limitations of current ECS products should be discussed with  
pregnant women and couples prior to testing and that “a responsible 
approach to practice would emphasize pre-test counseling . . . because 
you want to make sure that she understands what the limits of her  
options are before she gets the test.”68 
 
63. Id. 
64. Examples of prenatal genetic blood screening include the triple screen and 
quad screen, which measure maternal serum for risk factors associated with 
spina bifida, anencephaly, trisomy 21 (Down syndrome), and trisomy 18 
(Edwards syndrome).  Maternal Blood Screening for Birth Defects, March 
of Dimes, https://www.marchofdimes.com/ 
professionals/25079_1166.asp (last visited Jan. 3, 2013). 
65. Focus Group 4. 
66. Focus Group 1. 
67. Focus Groups 3–6. 
68. Focus Group 6. 
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V. Prenatal Applications of ECS: Expanding Tech-
nology and Options? 
Advocates of ECS suggest that it is preferable to conventional CS 
due to its disease coverage and applicability across ethnic populations.69 
As ECS products become increasingly available, a wider range of women 
and their partners may discover that they carry a recessive mutation 
that may be inherited by their children. The findings of this focus-group 
study suggest that the introduction of ECS into prenatal care presents 
challenges that both resemble and diverge from conventional approaches 
to prenatal CS. These challenges relate to timing of implementation, 
informed consent, counseling, and maternal attitudes and perceived  
responsibilities. Each challenge will be discussed in turn.  
In some ways, the promises and challenges of ECS that study partic-
ipants identified reflect long-recognized issues regarding the integration 
of genetic risk information into reproductive healthcare and are not 
unique to ECS technology. Historically, the evaluation of new prenatal 
screening technologies has advanced with the dual goal of increasing the 
amount and specificity of risk information along with reduction of 
costs.70 Hence, participants’ suggestion that prenatal care providers may 
be drawn to ECS because it provides more risk information at a lower or 
comparable cost to other CS platforms may reflect the likely  
continuation of this trend.71 As mentioned in the focus groups, the  
appeal of ECS may also reflect conservatism on the part of clinicians 
trying to avoid liability for not detecting genetic conditions prenatally.72 
However, existing problems of implementing and counseling for prenatal 
CS may be compounded by the timing of screening, volume of results, 
and rarity of diseases included on panels. 
Edelson has argued that the success of population-based CS  
programs may be dependent on “tight coupling between diagnosis and 
clinical outcome, the clear implications for specific action which the 
identified ‘carrier status’ has, and the relatively brief and well-defined 
time span within which persons have to act with regard to the  
information.”73 The findings of this study and previous research suggest 
that it is likely that most women will receive CS results during pregnan-
cy, which makes for a well-defined yet compressed decision-making 
 
69. Srinivasan, supra note 12, at 548. 
70. See generally Ryan A. Harris et al., Cost Utility of Prenatal Diagnosis and 
the Risk-Based Threshold, 363 Lancet 276 (2004). 
71. See supra Part V (discussing appeal of ECS to clinicians). 
72. See supra Part V (discussing defensive medicine). 
73. Paul J. Edelson, The Tay-Sachs Disease Screening Program in the U.S. as 
a Model for the Control of Genetic Disease: An Historical View, 7 Health 
Matrix 125, 132 (1997). 
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timeline.74 Hence, women who receive abnormal CS results in the context 
of pregnancy will need to consider whether to use prenatal diagnosis and 
whether to terminate or continue an affected pregnancy.75 The timing of 
the testing will impact the utility of the information provided, regardless 
of whether the technology is screening for a single gene mutation or for a 
number of recessive mutations. Thus, it is important that both clinicians 
and pregnant women view this technology in light of how timing of  
implementation can affect the choices that would follow. 
Further, the findings of this study suggest that challenges associated 
with informed consent for ECS will be significant. Many of these  
challenges are already anticipated in experiences with other non-invasive 
prenatal screening technologies such as CS for single gene disorders.76 
Some explanations for inadequate informed-consent processes for screening 
in the prenatal context include the brevity or absence of pre-test counsel-
ing and the common (thus potentially unremarkable) occurrence of blood 
draws during prenatal appointments.77 These challenges may reflect  
constraints on the ways in which prenatal appointments and practices are 
organized more than the risk assessment technologies in question.  
In addition to the parallels drawn between ECS and existing prena-
tal screening technologies, study participants also identified new 
challenges potentially posed by the integration of ECS into prenatal 
care. Research has demonstrated that women with known heritable  
genetic risk factors tend to be ambivalent about the range of reproduc-
tive options available to them, and their attitudes fluctuate as they 
encounter new stages in their reproductive journeys.78 As with the  
normalization of past reproductive genetic screening and diagnostic 
technologies,79 participants suggested that ECS may exacerbate an  
 
74. Clayton et al., supra note 16, at 625.  
75. See De Wert et al., supra note 15, at 225-26. 
76. See Ormond et al., supra note 22, at 542. 
77. K. E. Ormond et al., Information Preferences of High Literacy Pregnant 
Women Regarding Informed Consent Models for Genetic Carrier 
Screening, 75 Patient Educ. & Counseling 244, 245 (2009); Kate Reed, 
‘It’s Them Faulty Genes Again’: Women, Men and the Gendered Nature of 
Genetic Responsibility in Prenatal Blood Screening, 31 Sociology of 
Health & Illness 343, 345 (2009).  
78. Sarah Franklin & Celia Roberts, Born and Made: An 
Ethnography of Preimplantation Genetic Diagnosis 177 (2006); 
Michelle McGowan, Constructions of Good Motherhood in an Online 
Forum for Users of Preimplantation Genetic Diagnosis, in Motherhood 
Online 180-99 (Michelle Moravec ed., 2011); Allyn McConkie-Rosell et al., 
Influence of Genetic Risk Information on Parental Role Identity in 
Adolescent Girls and Young Women from Families with Fragile X 
Syndrome, 21 J. Genetic Counseling 59 (2012).   
79. Franklin & Roberts, supra note 78, at 166-68; see Nancy Press et al., 
Provisional Normalcy and “Perfect Babies”: Pregnant Women’s Attitudes 
Toward Disability in the Context of Prenatal Testing, in Reproducing 
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already complicated prenatal decision-making process by introducing 
more and rarer carrier traits to be evaluated, increasing the complexity 
of pre-test counseling and interpretation of results, and increasing the 
volume and uncertainty associated with positive results.80 As has been 
argued regarding the inclusion of three or more conditions in prenatal 
screening panels, “it is likely that efforts to educate screenees about an 
increasing number of diseases will not be as successful, as there will 
probably be a limit to the number of disease descriptions that even a 
highly educated screenee can recall after a single education session.”81 
This challenge may only be amplified in the context of ECS panels, 
which screen for upwards of 45 conditions at once.82 In addition, the 
range of diseases examined by ECS products further complicates the 
process of obtaining informed consent and may require substantially 
more time to review in comparison to more familiar prenatal evaluations. 
Thus, moving from population-based screening of single gene disorders to 
ECS panels which include screening for a large number of rare disease-
associated mutations may limit the effectiveness of counseling for  
pregnant women regarding reproductive decisions and amplify uncertainty 
about how to manage results concerning rare disorders. 
The inclusion of more disease risks in CS panels brings with it the 
increased possibility that more pregnant women will receive positive 
results, potentially making identification as a carrier “the new normal.” 
This new normal is likely to have implications for many more pregnancies, 
which in turn could impact women’s attitudes toward their pregnancies. 
One challenge that participants noted is that if some women are already 
under-informed about the kind of prenatal screening done, then unex-
pected positive results could be that much more challenging to assimilate 
into one’s frame of reference.83 This may reflect an understanding by  
genetics specialists, as Lyerly and colleagues have argued, that the drive 
to infuse more risk information into pregnancy is not always balanced 
 
Reproduction 46, 47-48 (Sarah Franklin & Helena Ragoné eds. 1998) 
(observing that maternal serum alpha fetoprotein screening has become 
routine); Rayna Rapp, Testing Women, Testing the Fetus: The 
Social Impact of Amniocentesis in America 29 (1999); see generally 
McGowan, supra note 78, at 180-99. 
80. See supra Part V (discussing complexity associated with genetic counseling 
and interpretation of ECS). 
81. Christine M. Eng et al., Prenatal Genetic Carrier Testing Using Triple 
Disease Screening, 278 JAMA 1268, 1271 (1997). 
82. See supra Part III (discussing the number of genetic conditions that ECS 
can evaluate). 
83. See supra Part V (discussing challenges patients may experience in using 
ECS results to inform prenatal decisions). 
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against the values of pregnant women and their families.84 Findings of 
this study suggest that under-informed patients receiving positive ECS 
results may be faced with unexpected and difficult decisions without 
adequate preparation. Some of these choices may concern the continua-
tion of a pregnancy and other potential costs of managing the risk. For 
instance, although ECS products are currently priced to be affordable at 
$99 to $450, follow-up procedures will be much more costly. The cost for 
follow-up in the form of genetic sequencing and prenatal testing may 
present significant barriers to making test results actionable.85 Being 
under-informed about the analytic limitations of the screen may also 
result in patients who accept ECS, receive negative results, and later 
have a baby with a genetic or chromosomal disorder that they believed 
to be ruled out by the screen.  
On the other hand, participants suggested that some pregnant  
women will be drawn to ECS in their quest to ensure the birth of a 
healthy baby. The expansion of CS may exacerbate what has been char-
acterized as the onus on women to take “genetic accountability” for their 
pregnancies by seeking genetic risk information.86 For these women, as 
has been documented with users of amniocentesis and prenatal CS for 
single gene disorders,87 there may be a sense of maternal obligation to 
learn what they can about the health of their prospective children and to 
make decisions regarding downstream implications of screening. This 
represents what Reed has characterized as a perceived responsibility by 
pregnant women to manage genetic risks to the fetus even when genetic 
material that confers risk is equally contributed by both men and women 
as carriers.88 However, as this study and others have shown, there is no 
prenatal screen or diagnostic tool that can rule out all possible reproduc-
tive risk factors.89 Participants raised the concern that the drive to ensure 
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health on the part of pregnant women may create unrealistic  
expectations—both concerning the technology in question and of the  
profession of medicine. These shifting expectations could, in some cases, 
have legal implications. For example, there is a potential for wrongful 
birth lawsuits to increase.90 Patients with babies with genetic disorders 
covered by ECS panels but who were not offered ECS may feel they were 
denied access to the most comprehensive risk information available.91 
There is also the possibility that false negative and false positive results of 
ECS could prompt wrongful birth lawsuits.92 
While the desire for the “perfectly normal” baby has been well-
documented in the social science literature,93 the marketing of ECS as a 
“universal” or “comprehensive” carrier test may contribute to conserva-
tism on the part of clinicians trying to avoid liability and increase 
patient tentativeness toward pregnancy in problematic and unrealistic 
ways. Juengst and colleagues have argued that “the logic of prevention 
has already walked some expanded carrier-screening companies across 
the equivocal bridge between phenotypic and genotypic prevention, 
though these are still firmly in the realm of individual rather than public 
health interventions.”94 Although study participants framed ECS in 
terms of the individual doctor-patient interaction, the question remains 
as to whether and how increasing identification of carriers through the 
expansion of population-based CS may contribute to shifting responsibil-
ity for genotypic prevention from the choices of individual women to 
social mandates to act in ways that would ensure fetal health as has 
been seen with the criminalization of pregnant drug users.95 
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Conclusion 
This study provides a vantage point from which to assess the  
potential impact of expanding the scope of population-based carrier testing 
in the prenatal setting. What we learned from focus groups with genetics 
professionals about expanding CS in the prenatal context suggests that 
clinicians and pregnant women will likely face similar logistical and  
psychosocial challenges as those that have arisen in the context of  
population-based CS for single gene disorders and other forms of prenatal 
screening. Although ECS promises to provide more information regarding 
one’s genetic risk factors, clinicians and their patients may encounter  
additional vulnerabilities in light of information provided by ECS,  
particularly if these tests provide unexpected results. Further research is 
indicated to anticipate the individual, professional, legal, and societal  
implications of expanded carrier screening. 
